NEW YORK (GenomeWeb News) — Genomic Health today said that Aetna has set payment rates for its Oncotype DX test for early-stage breast cancer patients.
 
Genomic Health said Aetna, which  began covering the test in August, has set rates for all of its plans for breast cancer patients for the test, which quantifies the odds of breast cancer recurrence and predicts the chances of the effectiveness of chemotherapy treatment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.